Bioneeds is dedicated to provide end-to-end biologics drug development services with its two distinct technology platforms:
Capabilities include development of recombinant proteins such as non-glycosylated proteins; glycoproteins and monoclonal antibodies derived from either bacterial or mammalian host expression systems.
Our preclinical platform is supported by the OECD GLP & AAALAC certified animal facilities.
We have the expertise to handle novel biologics, biosimilars and bio betters.
CQA Driven Process & Product Development
Well Characterized Products
RCG, MEME, AUS-FDA
Method Development; Validation; Sample Analysis
Animal Studies; Sample Analysis
Antibody Generation; Screening Assays; Confirmatory Assays; Neutralizing Antibody Assays
HCP; HCD; Others
Immunization; Purification; Characterization; Reactivity
Drug Development Platform
Codon optimization; clone stability; bioreactor suitability; titre; product quality
Cell culture & purification; critical process parameters; COGS
Analytical; bio/analytical; potency (compliance to standard guidelines & pharmacopeia)
Compliance to standard guidelines & pharmacopeia
Complete product development (starting with sequence) with tox material supply